Akebia Therapeutics is a fully integrated biopharmaceutical company based in Blue Ash, OH, dedicated to advancing new hope for people with kidney disease. Their team works tirelessly to address complications of kidney disease and deliver unique products to patients, including the innovative oral hypoxia-inducible factor prolyl hydroxylase inhibitor, vadadustat.
With a focus on collaboration and innovation, Akebia Therapeutics is a trusted leader in the renal community, leveraging Nobel Prize-winning science to develop groundbreaking treatments. Their commitment to protecting the kidneys and improving the lives of those affected by chronic kidney disease underscores their position as a pioneering force in the field of biopharmaceuticals.
Generated from the website